Identification | Back Directory | [Name]
Anordiol | [CAS]
1045-29-0 | [Synonyms]
Af-45 H-241 Af 45 (pharmaceutical) (17R)-2α-Ethynyl-A-nor-5α-pregn-20-yne-2β,17-diol A-Nor-5-alpha,17-alpha-pregn-20-yne-2-beta,17-diol, 2-ethynyl- A-Norpregn-20-yne-2,17-diol, 2-ethynyl-, (2-beta,5-alpha,17-alpha)- Dicyclopenta(A,F)naphthalene-1,7-diol, 1,7-diethynylhexadecahydro-8A,10A-dimethyl-, (1R,3as,3br,5as,7R,8as,8bs,10as)- Dicyclopenta(A,F)naphthalene-1,7-diol, 1,7-diethynylhexadecahydro-8A,10A-dimethyl-, (1R-(1alpha,3abeta,3balpha,5abeta,7alpha,8aalpha,8bbeta,10aalpha))- | [Molecular Formula]
C22H30O2 | [MDL Number]
MFCD01711296 | [MOL File]
1045-29-0.mol | [Molecular Weight]
326.472 |
Hazard Information | Back Directory | [Uses]
Anordiol is an antiestrogenic compound with weak estrogenic activity. It can reduce the parameters of uterine growth (including uterine wet weight, soluble protein content, and DNA content) induced by estradiol in rats and can also regulate the estrous cycle in rats. Anordiol holds potential application value in the research of antiestrogen-related diseases[1]. | [References]
[1] Chatterton RT Jr, et al. Anti-uterotrophic and folliculostatic activities of anordiol (2 alpha,17 alpha-diethynyl-A-nor-5 alpha-androstane-2 beta,17 beta-diol). Contraception. 1989 Mar;39(3):291-7. DOI:10.1016/0010-7824(89)90061-9 |
|
|